1 figure, 2 tables omitted
Dengue is caused by four antigenically related viruses (DENV-1, DENV-2, DENV-3, and DENV-4). Dengue fever is endemic in most tropical and subtropical areas of the world, and in 2007 nearly 1 million cases were reported in the Americas alone. Dengue infections commonly occur among U.S. residents returning from travel to endemic areas1- 4 and are more prevalent than malaria among returning travelers from the Caribbean, South America, South Central Asia, and Southeast Asia.5 This report summarizes information about dengue cases reported to CDC through two CDC-maintained passive surveillance systems: (1) the ArboNET surveillance system, a national CDC arboviral surveillance system maintained by CDC's Arboviral Diseases Branch and initially developed in response to the introduction of West Nile virus in the United States, and (2) a system maintained for decades by the CDC Dengue Branch (CDCDB), which collects information on all suspected dengue cases whose specimens are sent to the branch. During 2006-2008, a total of 1,125 unique reports were made to either ArboNET or CDCDB. Of these, the highest proportion of laboratory-confirmed and probable cases with known travel histories were in persons who reported travel to the Dominican Republic (121; 20%), Mexico (55; 9%), and India (43; 7%). Health-care providers should consider dengue in the differential diagnosis of patients with a history of travel to endemic areas within 14 days of fever onset.
Dengue cases are reported to ArboNET from state and metropolitan health departments. The dengue surveillance system at CDCDB receives reports of suspected dengue cases among U.S. travelers from clinicians and officials at state health departments, who forward patient specimens to CDC for diagnostic testing. Age, sex, birth date, and onset date are used to match cases reported to both systems, and duplicate cases are eliminated.
For both CDCDB and ArboNET, a case of laboratory-diagnosed infection (i.e., probable or laboratory-confirmed) in a resident of one of the 50 states or the District of Columbia (DC) who traveled in the 14 days before symptom onset to a dengue-endemic area outside the 50 states. Because autochthonous dengue transmission in the continental United States is uncommon, all cases reported to ArboNET or CDC are classified as travel-associated unless they are identified specifically as locally acquired.
Cases submitted to ArboNET are classified as probable or laboratory-confirmed by the reporting jurisdiction; specimens submitted to CDC are classified as probable or laboratory-confirmed based on testing conducted at CDCDB. Probable cases are defined by a single immunoglobulin M (IgM) specimen in late acute phase or convalescent phase of illness. Laboratory-confirmed cases are defined by a positive polymerase chain reaction (PCR) test result or by viral isolation.
During 2006-2008, 57 duplicate reports were reported to both ArboNET and CDCDB and were assigned to CDCDB. During that period, ArboNET received reports of 596 cases, of which 468 (79%) were reported as probable and 128 (21%) were reported as laboratory-confirmed.
During 2006-2008, CDCDB received a total of 529 specimens from 524 patients in 41 states and DC for dengue testing (153 in 2006, 272 in 2007, and 104 in 2008). Of the 529 specimens, 136 (26%) resulted in a diagnosis of dengue. Among those 136 specimens, 106 (78%) had elevated antidengue IgM antibodies (probable recent dengue infection), and 30 (22%) had a dengue virus identified in serum by either reverse transcription—polymerase chain reaction (RT-PCR) or viral isolation (confirmed acute dengue infection). Serotype specific data were available for those 30 cases, of which 14 were DENV-1, seven were DENV-2, six were DENV-3, and three were DENV-4. Results for 162 (31%) specimens were classified as indeterminate because blood samples were not collected within specified timeframes. Among the 215 patients (41% of all specimens received) whose laboratory results were negative (RT-PCR or IgM negative, or no virus isolated), 38 (18%) had evidence of past flavivirus infection. In addition, the amount of serum provided for 16 (3%) of the patients was insufficient for testing, and in one sample the infecting virus could not be identified.
The 596 case reports were received by ArboNET from 25 states; more than half (57%) were reported from three states: 178 (30%) from New York, 99 (17%) from Florida, and 61 (10%) from Texas. Among the 136 dengue-positive cases identified by CDCDB, 42 (31%) were submitted from New York, 17 (13%) from Massachusetts, 10 (7%) from Arizona, and 10 (7%) from Georgia. Males accounted for 52% of all cases reported to ArboNET and 54% of positive specimens to CDCDB. Median age of patients was similar for both systems; 40 years and 42 years, respectively.
Of the 732 confirmed and probable cases from ArboNET and CDCDB combined (596 cases from ArboNET and 136 positive cases from CDC), history of travel was reported by 649 persons (89%), among whom country-specific travel information was available for 613 (95%). By region, 262 persons (43%) had traveled to the Caribbean; 208 (34%) to Mexico, Central America, or South America; 131 (21%) to Asia and the Pacific; and 12 (2%) to Africa. By country, 121 persons (20%) reported travel to the Dominican Republic, 55 (9%) to Mexico, and 43 (7%) to India during the 14 days before illness onset. One laboratory-confirmed case reported to ArboNET from Texas in 2008 was characterized as “not imported,” with no travel history, and might have represented autochthonous dengue transmission.
For ArboNET cases, the type of clinical syndrome was recorded in 596 cases; 429 (72%) were categorized as uncomplicated fever, 95 (16%) as dengue hemorrhagic fever or dengue shock syndrome, 56 (9%) as other syndrome or unknown, and 16 (3%) as dengue with hemorrhage. For CDCDB cases, clinical syndrome was recorded for 54 (40%) of 136 laboratory-diagnosed cases; 32 (59%) were classified as dengue fever, four (7%) cases as dengue hemorrhagic fever, and no cases of dengue shock syndrome. The most frequently reported signs and symptoms included 77 (57%) cases with fever, 57 (42%) with headache, and 55 (40%) with body ache. Among the 136 CDCDB cases, 27 (20%) included at least one hemorrhagic symptom (e.g., petechiae, purpura, hemoptysis, hematemesis, hematuria, vaginal bleeding, bleeding gums, or epistaxis). A higher proportion of cases submitted to ArboNET (292; 49%) resulted in hospitalization compared with CDCDB cases (26; 19%). One travel-associated dengue fatality was laboratory confirmed by CDCDB.
R Luce, DVM, A Rivera, MS, H Mohammed, PhD, KM Tomashek, MD; Dengue Br, J Lehman, Arboviral Diseases Br, Div of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, CDC.
During 2006-2008, an average of 244 confirmed and probable travel-associated dengue cases were identified by ArboNET or CDCDB annually, compared with an annual average of 33.5 cases (range:13-77 cases) identified during 1990-2005. Most of this increase likely resulted from the 2003 addition of dengue reporting to the ArboNET surveillance system, which supplements CDCDB.6 However, a portion of the increase also likely resulted from substantial increases in dengue incidence throughout subtropical and tropical areas of the world, including the Americas.6 During 2006-2008, dengue outbreaks were reported in numerous countries, including Belize, Brazil, Costa Rica, Cuba, Ecuador, El Salvador, Guadeloupe, India, Madagascar, Martinique, Mexico, Nicaragua, Pakistan, Paraguay, the United States (Puerto Rico, U.S. Virgin Islands), Venezuela, and multiple island nations in the South Pacific. Most U.S. residents become infected during travel to tropical and subtropical areas outside the continental United States, although autochthonous transmission has been documented on multiple occasions since 1980 in Texas,7,8 during 2001-2002 in Hawaii,9 and during 2009-2010 in Florida.10
Dengue has an incubation period of 3-14 days. Because U.S. travelers spend a median of 10 nights abroad, many returning travelers who are infected could be viremic and able to infect endemic Aedes spp. vector mosquitoes (principally Ae. aegypti and Ae. albopictus) in some locations in the continental United States, thus creating the potential for localized dengue transmission. Clinically recognized cases of travel-associated dengue likely underestimate the risk for importation because many dengue infections are asymptomatic or mildly symptomatic (see sidebar).
The findings in this report are subject to at least three limitations. First, these surveillance results likely are subject to underreporting because both CDCDB and ArboNET are based on passive reporting (i.e., each rely on public health jurisdictions and health-care providers to detect and report infection) and dengue was designated a nationally notifiable disease in the United States in 2010, after the ending date of this report. Second, cases submitted to ArboNET were classified as either probable or laboratory-confirmed by the reporting jurisdiction largely based on interpretation of laboratory results from private laboratories using several different laboratory diagnostic tests, which might have affected classification and reporting of results. Finally, travel histories and clinical information were not available for all cases and might not have been representative of all persons with travel-associated dengue.
Travelers to tropical areas can reduce their risk for dengue by avoiding exposure to mosquitoes. No vaccine is available for preventing dengue infection. Persons traveling to areas where dengue is endemic should use insect repellents, wear protective clothing, and reside in facilities with screens and air conditioning when available. Preventing travel-associated dengue not only benefits the traveler, but also helps prevent the introduction of dengue virus into tropical areas and subtropical areas of the United States (primarily the southeastern states), where vector mosquitoes could transmit the virus indigenously.
This report is based, in part, on contributions by state and local health departments, and by surveillance staff members of the Arboviral Diseases Br and the Dengue Br at CDC.
After the Council of State and Territorial Epidemiologists (CSTE) recommended addition of dengue to the list of nationally notifiable diseases, in January 2010, CDC added dengue to the list. Public health jurisdictions are encouraged to report cases via the ArboNET system. Health-care providers are encouraged to submit specimens to the CDC Dengue Branch for diagnostic testing, as follows:
Obtain an acute phase (0—5 days after onset of symptoms) serum sample, for directly detecting dengue virus.
Obtain a convalescent phase serum sample, preferably 1—2 weeks after the first sample, for detecting antidengue antibody. Serologic testing can detect diagnostic levels of antidengue immunoglobulin M antibody for approximately 30 days after symptom onset and longer in some patients.
To obtain viral identification and serologic diagnosis, send specimens through state or territorial health departments to the Dengue Branch, Division of Vector-Borne Infectious Diseases, National Center for Infectious Diseases, 1324 Calle Cañada, San Juan, PR 00920-3860; telephone 787-706-2399; fax 787-706-2496.
Attach a summary of clinical and epidemiologic information to all serum samples; be sure to include date of disease onset, date of sample collection, and detailed recent travel history.
Additional information is available at http://www.cdc.gov/dengue/resources/testpoleng_2.pdf.
Dengue infections commonly occur among U.S. residents returning from travel to endemic areas and are more prevalent than malaria among returning travelers from the Caribbean, South America, South Central Asia, and Southeast Asia.
What is added by this report?
During 2006-2008, an average of 244 confirmed and probable travel-associated dengue cases annually were identified by two CDC-maintained passive surveillance systems, substantially more than the 33.5 cases (range: 13-77 cases) identified annually during 1990-2005.
What are the implications for public health practice?
Health-care providers should consider dengue in the differential diagnosis of patients with a history of travel to endemic areas within 14 days of fever onset.
Travel-Associated Dengue Surveillance—United States, 2006-2008. JAMA. 2010;304(7):736-738. doi: